NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences ...

A webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony ...

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs.

On Wednesday, Piper Sandler reaffirmed its Overweight rating on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) with a steady price target of $44.00. The firm's positive stance... On Wednesday ...

Antonio Gracias, a director at Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), has sold a significant portion of the company's stock, according to a recent SEC filing. The... In a recent ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Harmony Biosciences Holdings ...

About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have ...

DelveInsight's 'Myotonic Dystrophy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline myotonic ...